{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:52:57Z","timestamp":1761519177629,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.breast.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T23:00:37Z","timestamp":1482274837000},"page":"247-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Patient database analysis of fulvestrant 500\u00a0mg in the treatment of metastatic breast cancer: A European perspective"],"prefix":"10.1016","volume":"32","author":[{"given":"Paolo","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolai","family":"Maass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finlay","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Montonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2016.12.002_bib1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(11)61351-2","article-title":"Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis","volume":"378","author":"Forouzanfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2016.12.002_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/aje\/kwp036","article-title":"Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study","volume":"169","author":"Setiawan","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.breast.2016.12.002_bib3","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.ejca.2012.10.004","article-title":"The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer","volume":"48","author":"Cardoso","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2016.12.002_bib4","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib5","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib6","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib7","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib8","first-page":"3867","article-title":"A\u00a0potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2016.12.002_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0070017","article-title":"Similarities and distinctions in the mode of action of different classes of antioestrogens","volume":"7","author":"Wakeling","year":"2000","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.breast.2016.12.002_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials","volume":"98","author":"Robertson","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2016.12.002_bib11","first-page":"6739","article-title":"Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer","volume":"61","author":"Robertson","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2016.12.002_bib12","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib13","doi-asserted-by":"crossref","first-page":"djt337","DOI":"10.1093\/jnci\/djt337","article-title":"Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial","volume":"106","author":"Di Leo","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2016.12.002_bib14","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1200\/JCO.2015.61.5831","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study","volume":"33","author":"Ellis","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-004-4776-0","article-title":"Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant","volume":"92","author":"Robertson","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2016.12.002_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2016.12.002_bib17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1185\/03007995.2014.908829","article-title":"Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)\/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012","volume":"30","author":"Swallow","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.breast.2016.12.002_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1185\/03007995.2014.887002","article-title":"Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer","volume":"30","author":"Andre","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.breast.2016.12.002_bib19","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.12.002_bib20","unstructured":"European Medicines Agency. Fulvestrant summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000540\/WC500021174.pdf. Last updated 19 May 2015. Accessed (09.08.15.)."},{"key":"10.1016\/j.breast.2016.12.002_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/cer.12.43","article-title":"Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey","volume":"1","author":"DeKoven","year":"2012","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.breast.2016.12.002_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1185\/03007995.2011.650503","article-title":"Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe","volume":"28","author":"Zhao","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.breast.2016.12.002_bib23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2016.12.002_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616302648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616302648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:37:23Z","timestamp":1760776643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977616302648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":24,"alternative-id":["S0960977616302648"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2016.12.002","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient database analysis of fulvestrant 500\u00a0mg in the treatment of metastatic breast cancer: A European perspective","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}